item managements discussion and analysis of financial condition and results of operations general emisphere is a drug delivery company focused on the discovery and application of proprietary synthetic chemical compounds that enable the oral delivery of therapeutic macromolecules and other compounds that are not currently deliverable by oral means 
since its inception in  the company has devoted substantially all of its efforts and resources to research and development conducted on its own behalf and through collaborations with corporate partners and academic research institutions 
the company has had no product sales to date 
the major sources of the company s working capital have been proceeds from its initial public offering in  a second public offering in february  a third public offering in july  private equity financing  the latest of which occurred with an affiliate of elan in october  reimbursement of expenses and other payments from corporate partners  the registered sale of one million shares of common stock to two institutional investors in april  and income earned on the investment of available funds 
the company s operations are not significantly affected by inflation or seasonality 
on february  the company and lilly announced that they entered into a strategic alliance the lilly strategic alliance to utilize emisphere s technologies for the improved delivery of certain lilly therapeutic proteins with a focus on oral delivery 
the major therapeutic focus of the collaboration is in the area of endocrinology  including growth disorders 
initially  lilly is committing limited funds to the company for research on delivery of two proteins 
the lilly strategic alliance contemplates that lilly may ultimately exercise options to license the applicable carriers and market the products utilizing the combined technologies 
if the options are exercised  the company may receive from lilly milestone and other payments aggregating  together with initial funding  up to million  as well as future royalty payments 
the lilly strategic alliance also contemplates that the company could receive further payments for other delivery applications if the focus of the lilly strategic alliance is expanded beyond the two specified therapeutic proteins or to non oral applications 
results of operations the company has since its inception generated significant losses from operations 
the company does not expect to achieve profitability in the foreseeable future 
profitability will ultimately depend on the company s ability to develop its lead products  in conjunction with the elan joint venture and the lilly strategic alliance or to develop other products in conjunction with other partners 
there can be no assurance that the development will be completed or if completed  any regulatory agency will approve the final product 
even if final products are developed and approved  there is no assurance that sales will be sufficient to achieve profitability 
if development of such products is not achieved or approval not granted  the company s prospects will be materially affected 
the ability of the company to reduce its operating losses in the near term will be dependent upon  among other things  its ability to attract new pharmaceutical and other companies who are willing to provide funding to the company for a portion of the company s research and development with respect to specific projects 
while the company is constantly engaged in discussions with pharmaceutical and other companies  there can be no assurance that the company will enter into any additional agreements or that the agreements will provide research and development revenues to the company 
fiscal compared to fiscal revenues increased by approximately  the majority of the increase in contract research revenue was attributable to increased revenues from the elan joint venture of million as the company provided additional services to the joint venture 
the company also recognized contract revenues from the lilly strategic alliance  and from two pharmaceutical companies for which the company performed feasibility studies 
total operating expenses for the fiscal year ended july  increased by  or  as compared to fiscal the details of the increase are as follows research and development costs increased by approximately  or  in fiscal as compared to fiscal this increased is mainly attributable to increased personnel and related expenses associated with the company s development of an oral heparin formulation and work performed in connection with the lilly strategic alliance 
the company also experienced an increase in funding of outside consultants and universities engaged to conduct studies to help advance the company s scientific research efforts 
the company believes that this level of research and development spending will continue for the foreseeable future and may increase if operations are expanded 
the increase of  in the loss in elan emisphere joint venture represents the company s pro rata portion of the ventures loss for the period 
no loss was experienced in the comparable period as the venture did not commence operations until september general and administrative expenses increased by approximately  or  in the fiscal as compared to fiscal this increase is primarily attributable to an increase in legal and professional fees incurred in connection with the finalization of the elan emisphere joint venture and the agreement with lilly 
the company also experienced an increase in personnel and related expenses 
the increase was partially offset by a decrease in expenses relating to services provided by outside consultants 
the company recorded expenses of approximately  in connection with the granting of options as compensation to business consultants in the fiscal year compared to  in fiscal as a result of these factors  the company s operating loss increased by  or  from fiscal to fiscal the company does not expect to generate an operating profit  and may possibly generate larger losses  in the foreseeable future 
the company s other income for the fiscal increased by approximately  or  from fiscal this was primarily due to a larger investment portfolio 
based on the above factors  the company sustained a net loss for fiscal of  a increase over fiscal loss of  fiscal compared to fiscal revenue increased by approximately  the revenue consisted of a payment of  from elan to reimburse the company for certain research and development costs  and payments from two other pharmaceutical companies for which the company performed feasibility studies 
the recognition of the revenue from elan was for work emisphere performed on development of an oral formulation of heparin 
total operating expenses for the fiscal year ended july  increased by approximately  or  as compared to fiscal the details of the increase are as follows research and development costs increased by approximately  or  in fiscal as compared to fiscal the increase is mainly attributable to the company s clinical development program for heparin 
the clinical development program consisted of work performed to file an investigational new drug application ind application with the fda for the commencement of a phase i clinical trial  and the performance of a double blind controlled dose escalation study in humans  as well as other studies undertaken to support the development of an oral formulation of heparin 
the higher costs associated with the clinical development program relating to heparin were partially offset by a decrease in funding of outside consultants and universities  not associated with the clinical program  engaged to conduct studies to help advance the company s scientific research efforts 
the company also experienced a decrease in personnel and related expenses due  in part  to a staff reduction in may the company believes that this level of research and development spending will continue for the foreseeable future and may increase if operations are expanded 
general and administrative expenses increased by approximately  or  in fiscal as compared to fiscal this increase is primarily attributable to an increase in expenses relating to services provided by outside business consultants 
the company recorded expenses of approximately  in connection with the granting of stock and options as compensation to business consultants for assisting the company in discussions and negotiations with pharmaceutical companies 
the company also experienced an increase in legal and other professional fees incurred in connection with  among other things  the settlement of a class action lawsuit and the elan joint venture 
as a result of these factors  the company s operating loss decreased by approximately  or  from fiscal to fiscal the company does not expect to generate an operating profit  and may possibly generate larger operating losses  in the foreseeable future 
the company s other income for fiscal increased by approximately  or  from fiscal this was primarily due to a larger investment portfolio as a result of recent equity financing and research and development revenues of  received from elan 
based on the above  the company s net loss for fiscal was  a decrease over fiscal s loss of  liquidity and capital resources as of july  the company had working capital of approximately  total cash  cash equivalents and marketable securities were approximately  an increase of  compared to the company s position at july  the increase in the company s cash  cash equivalents and marketable securities was primarily due to the proceeds of approximately  in a public offering of  shares of the company s common stock in july  receipt of approximately  from the elan joint venture to reimburse the company for research and development costs  receipt of approximately  in payments under the lilly agreement and feasibility studies revenue  partially offset by cash used to fund operations in fiscal the company entered into a ten year noncancelable lease for new office and laboratory space commencing august the annual minimum rental is approximately  the company also anticipates capital expenditures of approximately  in connection with the occupation of the new space during the next twelve months 
the company expects to continue to incur substantial research and development expenses associated with the development of the company s oral drug delivery system 
as a result of the ongoing research and development efforts of the company  management believes that the company will continue to incur operating losses and that  potentially  such losses could increase 
the company expects to need substantial resources to continue its research and development efforts 
in addition  the company is obligated to fund one half of the elan joint venture s cash needs upon the venture s request 
the company expects to commence funding the venture during the next quarter 
funding requirements are established to initially be  over the next six months and depending upon the agreed timing and scope of future research and development efforts may increase substantially thereafter 
pursuant to the elan joint venture  the company and elan share the financial benefits and expense obligations of the venture on a basis 
the company expects the research funding from lilly to approximate the costs to be incurred by the company in connection with the development of the lilly therapeutic proteins 
see collaboration agreements under present operating assumptions  the company expects that cash  cash equivalents and marketable securities will be adequate to meet its liquidity and capital requirements through fiscal thereafter  the company would need to seek additional funds  primarily in the public and private equity markets and  to the extent necessary and available  through debt financing 
the company has no firm agreements with respect to any additional financing and there can be no assurance that the company would be able to obtain adequate funds on acceptable terms 
if adequate funds were not available  the company would be required to delay  scale back  or eliminate one or more of its research and development programs  or obtain funds  if available  through arrangements with collaborative partners or others that may require the company to relinquish rights to certain of its technologies  product candidates  or products that the company would not otherwise relinquish 
the company does not maintain any credit lines with financial institutions 
impact of the adoption of recently issued accounting standards in february  the financial accounting standards board issued financial accounting standard no 
earnings per share sfas 
sfas will require the company to replace the current presentation of primary per share data with basic and diluted per share data 
currently  outstanding common stock equivalents are antidilutive and therefore management estimates that the future adoption of sfas will not have a material impact on the company s per share data 
sfas will be adopted by the company for periods ending after december item a 
not applicable 
